Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioTechnique Launches Phase Two of Manufacturing Partnership | Contract Pharma
Breaking News, Collaborations & Alliances

BioTechnique Launches Phase Two of Manufacturing Partnership

Will manufacture a commercially-available vaccine product in a new, shelf-stable dosage form

BioTechnique has launched the second phase of manufacturing in partnership with a major, international not-for-profit organization. Under this partnership, BioTechnique will manufacture a commercially-available vaccine product in a new, shelf-stable dosage form. In the first phase of manufacturing, BioTechnique produced the same vaccine product in late 2015. The vaccine met all analytical and release testing specifications and entered the clinic in early 2016.

“We are very pleased to support a major non-profit trust in bringing their novel dosage form to market,” said John Clapham, chief executive officer, BioTechnique. “With the continuation of this live attenuated virus manufacturing partnership, we have broadened our ability meet demand from our customers who need a reliable contract manufacturing partner.”

Located in Madison, WI, BioTechnique’s successful completion of its first project marked its official transition into an operational contract manufacturing organization (CMO) with expertise in cytotoxic and highly potent sterile injectable manufacturing. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters